 "Dr Reddy's Labs forays into Colombia")
Dr Reddy’s Laboratories Ltd has forayed into Colombia with its portfolio of high quality and affordable medicines for cancer patients.
“Our company has a track record of staying committed to the markets we serve. We are delighted to make a beginning towards serving the unmet needs of patients in Colombia. Our initial focus would be to provide access to affordable cancer medicines to patients through our proven portfolio of oncology products,” said M V Ramana, executive vice president and head, branded markets, global generics of Dr Reddy’s Laboratories.
Dr Reddy’s, one of the leading generic oncology companies in India, is the second largest generic oncology injectable company by value in the US, according to IMS Health 2015. Over the years, the company has been expanding its international business and is currently present in 26 countries.
Dr Reddy’s operates in all major regions across the world with the major markets being - USA, India, Russia & CIS countries, and Europe with a workforce of over 20000 employees. The company’s more than 20 manufacturing facilities are supported by five technology development centres, two integrated product development centres and three research & development (R&D) centres.
Through its three businesses - pharmaceutical services & active ingredients, global generics and proprietary products - Dr Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Considered to be one of the global leaders in the generic industry, Dr Reddy’s focuses on making generic and complex products across the major therapeutic areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%